Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres.

Microspheres of polymers like poly(lactic-co-glycolic acid) (PLGA) have been studied as a vehicle for controlled release vaccines. They require materials and processes that might change the protein antigenicity. Lactic acid is produced during microsphere degradation that occurs in tandem with protein liberation. In addition, most of the proteins that have been used in microencapsulation studies contain Thimerosal((R))(TM) and this can introduce another undesirable effect for their stability. We demonstrated in vitro that the thiosalycilic acid (TSA), produced after the reduction of TM by lactic acid, reduces the S-S bridge of the previously incubated diphtheric toxoid (Dtxd). This reduction is immediately followed by blocking the two -SH formed by the same TSA molecules. In the light of these conclusions it is necessary now, to reinterpret the in vitro protein degradation-stabilization data in the presence of PLGA microspheres, mainly for those proteins which contain S-S. We propose that all the PLGA microspheres microencapsulation studies and protein structural considerations should be done in the absence of TM as preservative.

Ionic interfaces and diphtheria toxoid interactions.

We present here a systematic study on the purification of the diphtheria toxoid (Dtxd) produced at the Instituto Butantan, by adding only one step on the entire process of its production. Aliquots of 1.0 ml of Dtxd were added to an equal amount of Q-Sepharose previously equilibrated with 500 mM Tris, pH 5.0-9.0 (increments of 0.5 pH units). The best condition for the Dtxd monomer adsorption was achieved at pH 9.0. The best condition for desorption was obtained with 300 mM NaCl. After studying the gel binding capacity for Dtxd, a column (C20/20) equilibrated with 500 mM Tris, pH 9.0, was prepared. The purification factor for Dtxd was 1.5. The final recovery of Dtxd was 68.75%, with 90.31% purity. The process methodology presented here is a very realistic sequence of separation steps, which is perfectly compatible with the production requirements. Vaccination with "toxoid highly purified toxin" is known to confer a strong immunity on people in the absence of undesirable reactions, which led experts of European Pharmacopoeia to recommend its use both for children and adult vaccination.

Ionic interfaces and diphtheria toxoid interactions

We present here a systematic study on the purification of the diphtheria toxoid (Dtxd) produced at the Instituto Butantan, byadding only one step on the entire process of its production. Aliquots of 1.0 ml of Dtxd were added to an equal amount of QSepharosepreviously equilibrated with 500mM Tris, pH 5.0–9.0 (increments of 0.5 pH units). The best condition for the Dtxdmonomer adsorption was achieved at pH 9.0. The best condition for desorption was obtained with 300mM NaCl. After studyingthe gel binding capacity for Dtxd, a column (C20/20) equilibrated with 500mM Tris, pH 9.0, was prepared. The purification factorfor Dtxd was 1.5. The final recovery of Dtxd was 68.75%, with 90.31% purity. The process methodology presented here is a veryrealistic sequence of separation steps, which is perfectly compatible with the production requirements. Vaccination with ‘‘toxoidhighly purified toxin’’ is known to confer a strong immunity on people in the absence of undesirable reactions, which led experts ofEuropean Pharmacopoeia to recommend its use both for children and adult vaccination.